PATENT scope is being narrowed by the courts, but it's being broadened by patent offices, which knowingly reduce legal certainty. They know that many patents will never be tested in courts, only outside courts (pre-settlements and cross-licensing). There's lots more about US cases and laws in our latest daily links and it's more of the same, i.e. courts throwing out lawsuits that involve US patents. Sometimes these patents don't even reach the courts because they're invalidated before a lawsuit can even be filed. Sometimes the plaintiff is forced to compensate the defendant. Patent Trial and Appeal Board (PTAB) inter partes reviews (IPRs) are still being targeted by patent extremists, who habitually try to impede patent justice, i.e. invalidation of bogus ones. "On Monday, the U.S. Supreme Court granted a petition for writ of certiorari to take up Dex Media Inc. v. Click-to-Call Technologies," Steve Brachmann (Watchtroll) wrote, "on appeal from the Court of Appeals for the Federal Circuit. The case will ask the nation’s highest court to determine whether 35 U.S.C. €§ 314(d), which states that decisions to institute inter partes review (IPR) proceedings at the Patent Trial and Appeal Board (PTAB) are final and non-appealable..." (e.g. to the Federal Circuit or even SCOTUS)
"Germany's constitutional considerations are being assessed by the FCC, which is heckled and manipulated, as usual, by Team UPC."Europe is a different story although similarities exist, e.g. appeals coming under attack by sending judges to Haar and limiting their authority. Can they put an end to European Patents being granted in defiance of the EPC? The EPO has already tried to replace them all with the UPC, but it isn't happening. Germany's constitutional considerations are being assessed by the FCC, which is heckled and manipulated, as usual, by Team UPC. Lies are being told about it every month. It has become rather sick.
The EPO is meanwhile proceeding with its suicide plan. Decline in patent quality (and more fake patents granted based on algorithms) is covered up while veteran examiners leave or get pushed out. The EPO has tweeted a link to this (warning: epo.org
link) "vision of sustainability," adding: "The EPO Strategic Plan 2023 has been unanimously adopted! Have a look at what we, together with the EPO’s stakeholders, envisage for the coming years..."
It's "unanimously adopted" by patent maximalists; as we noted before, the EPO disregarded input in most European languages and from most stakeholders that include the public. The EPO only listens to the patenting and litigation 'industry', including the foreign one.
Microsoft and IBM, as expected, have decided to basically reclassify a lot of things to bypass 35 U.S.C. ۤ 101 at the U.S. Patent and Trademark Office (USPTO). Team Campinos/Battistelli at the European Patent Office (EPO) actively encourages violating the EPC and their media ally, the patent trolls' front group IAM, helps promote software patents in Europe using the "HEY HI" magic wand as recently as this week. To quote:
The UK’s IPO recently released a report on worldwide AI patenting activity, which it combined with a deep dive into the local landscape and how it compares to other countries. The study complements WIPO’s Technology Trends paper which we analysed to produce a top 10 takeaways piece earlier in the year.
The data analysed for the UKIPO report was pulled from the EPO’s PATSTAT product. The dataset consists of over 160,000 patent applications and 85,000 patent families.
[...]
IBM has the largest AI portfolio, trailed by Microsoft
Globally, IBM has the largest AI portfolio (by patent families). Although American companies take the top two spots, Asian businesses are highly represented in this list.
Accelerating the prosecution of a patent application can be useful.
The European Patent Office (EPO) has dismissed an appeal from Apple, ruling that one of its applied-for patents is unpatentable...
"On 19 June 2019 the Dutch District Court of The Hague – the Court with exclusive jurisdiction over patent matters in the Netherlands – issued a decision in merits proceedings between Eli Lilly & Company and Fresenius Kabi regarding Fresenius’ pemetrexed product (a machine translation as published by Mattie de Koning of Simmons is found here).
The product ‘Pemetrexed Fresenius Kabi’ is practically identical to Lilly’s pemetrexed product Alimta, apart from the fact that it contains the tromethamine salt instead of the disodium salt of pemetrexed. The question in many of the pemetrexed proceedings has been whether a pemetrexed product with a different salt falls within the scope of Lilly’s patent, which specifically claims disodium as the salt to be used in a combination therapy with vitamin B12 or a derivative thereof.
Other than in almost all preceding decisions, the Dutch Court ruled that there is no infringement of Lilly’s patent because tromethamine cannot be considered equivalent to disodium. A copy of the Dutch decision can be found here.
The BVerfG has today announced here that its Second Senate will hold an oral hearing in that first case (“ECB bond purchase program”) on 30 and 31 July 2019.
What do European patent attorneys have nightmares about? Trying to achieve re-establishment of rights at the EPO must be among the list. A decision of the Legal Board of Appeal (J 05/18), published this week, is a reminder that even with the best systems in place, an isolated error by any representative involved in the case may be catastrophic.
In some jurisdictions, the test for reinstating an application following refusal due to a missed deadline can be relatively low. At the UK IPO, for example, it is merely necessary to demonstrate that the failure to meet the deadline was "unintentional" (UKPA Section 20A). At the EPO, the test is considerably higher. The applicant must show that the deadline was missed despite "all due care" having been taken.
[...]
The board of appeal (BA) identified the misreading of the email regarding the applicants "interest in further processing" as the critical mistake leading to the missed deadline. The BA was of the view that the presence of a "well-functioning system" was therefore not decisive in this case. In the BA's view, the letter checked by the US representative, did not give "the slightest indication that the EP representative had already been instructed to request further processing. Quite the contrary, this document clearly demonstrated that no action had been taken at that stage" (r.1.2.3). Furthermore, whilst such an obvious mistake by an assistant may have been excusable, the BA could not excuse a representative for making such a mistake (r.1.2.5).
Therefore, the isolated mistake on behalf of the US attorney in misreading the letter was considered to demonstrate lack of all due care, regardless of any systems that may have been in place. The appeal was dismissed.